Maddala Madhavi

Maddala Madhavi

Auto-generated profile, based on publicly available information

Maddala Madhavi

Department of Zoology, Osmania University, Hyderabad - 500007, Telangana State, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2022 in Molecular Simulation
Verified
Journal Article
Closed access
MYManasi Yadav
Manasi Yadav
Mohnad AbdallaMohnad Abdalla
Mohnad Abdalla
MMMaddala Madhavi
Maddala Madhavi
ICIshita Chopra
Ishita Chopra
ABAnushka Bhrdwaj
Anushka Bhrdwaj
SSSanjeev Kumar Singh
Sanjeev Kumar Singh
Colorectal cancer is the third most frequent cause of cancer worldwide and is more prevalent in older individuals of all ages. The recent statistics from World Health Organisation (WHO) on cancer accounted for 1.93 million new cases of colorectal cancer alone, in 2020[1]. The exact cause of this disease is still unknown; however, obesity, sedentary lifestyle, and changed food consumption habit are thought to be driving forces. Earlier clinical studies have found non-steroidal anti-inflammatory drugs (NSAIDs) to be potent in treating colorectal cancer by inhibiting cyclooxygenase enzyme, and further research ascertained cyclooxygenase-2 gene (COX-2) inhibitors to be the most effective chemotherapy treatment. The aim of this study is to find the most effective inhibitor with a superior affinity against COX-2 protein and its pharmacological profile. The pre-established compound, parecoxib (PubChem ID: 119828) was taken up for Structure-based Virtual Screening to identify a novel compound (PubChem ID: 10151468) that has a strong binding affinity than the established compound. Additionally, the comparative studies of both the screened and established compounds were examined using the MD simulation approach to confirm structural stability. Our conclusion suggests that the virtual screened compound (PubChem ID: 10151468) could be a potential therapeutic for the treatment of colorectal cancer.

12 March 2024 in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
KSKhushboo Sharma
Khushboo Sharma
UPUmesh Panwar
Umesh Panwar
MMMaddala Madhavi
Maddala Madhavi
IJIsha Joshi
Isha Joshi
ICIshita Chopra
Ishita Chopra
SSSanjeev Kumar Singh
Sanjeev Kumar Singh
Background: The current study recognizes the significance of estrogen receptor alpha (ERα) as a member of the nuclear receptor protein family, which holds a central role in the pathophysiology of breast cancer. ERα serves as a valuable prognostic marker, with its established relevance in predicting disease outcomes and treatment responses. Methods: In this study, computational methods are utilized to search for suitable drug-like compounds that demonstrate analogous ligand binding kinetics to ERα. Results: Docking-based simulation screened out the top 5 compounds - ZINC13377936, NCI35753, ZINC35465238, ZINC14726791, and NCI663569 against the targeted protein. Further, their dynamics studies reveal that the compounds ZINC13377936 and NCI35753 exhibit the highest binding stability and affinity. Conclusion: Anticipating the competitive inhibition of ERα protein expression in breast cancer, we envision that both ZINC13377936 and NCI35753 compounds hold substantial promise as potential therapeutic agents. These candidates warrant thorough consideration for rigorous In vitro and In vivo evaluations within the context of clinical trials. The findings from this current investigation carry significant implications for the advancement of future diagnostic and therapeutic approaches for breast cancer.